Replies to post #13122 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

As of mid 2014:

There were 15 companies publicly pursuing the biosimilar for Avastin with Amgen in the lead.

There were 27 companies publicly pursuing the biosimilar for Enbrel with Sandoz/Samsung Biopsis in the lead.

There were 21 companies publicly pursuing the biosimilar for Herceptin with Amgen in the lead.

There were 15 companies publicly pursuing the biosimilar for Humira with Amgen in the lead.

There were 35 companies publicly pursuing the biosimilar for Rituxan with Boehringer in the lead.



BioXpress Therapeutics S. A. (Switzerland) is currently developing biosimilars for abatacept, adalimumab, etanercept, golimumab, infliximab, and tocilizumab.


From Celltrion PR:

Anti-inflammatory fusion proteins such as Enbrel (etanercept, Amgen/Pfizer) and Orencia (abatacept, BMS) represent another prime target for biosimilars development as both products are successful treatments for rheumatoid arthritis and psoriasis

If that's true, you can count on Samsung and LG would be right behind them. Celltrion is confusing because they actually produce abatacept for BMS. Simcere (China) is under contract to produce it for Asia.

I really think there should be some intelligent discussion of why Baxter has terminated the 2 drugs in process and never even sniffed at the additional 3.

I'm sure it's this board's impression that Baxter gave back the two drugs because they would have made way too much money.

Does anyone here remember what Wheeler said when Baxter returned M-511 and how Momenta would advance it? Where is M-511 now? Gone.....